Keyphrases
Lactams
100%
Dual β-lactams
100%
Multidrug-resistant
100%
Mycobacterium Abscessus
100%
Complex Infection
22%
Peptidoglycan
12%
Imipenem
12%
Synergistic Effect
12%
β-lactamase Inhibitor
12%
Cystic Fibrosis
12%
Ceftazidime
12%
Pharmacokinetic Analysis
12%
Remodeling Enzymes
12%
β-lactamase
10%
Molecular Mechanism
10%
Repressor
10%
Peptidoglycan Remodeling
10%
Hospital-acquired Infection
6%
Induced mutation
6%
Mouse Model
6%
Carbapenems
6%
Treatment Goals
6%
Rapid Diagnostic Test
6%
Spontaneous mutant
6%
Hollow-fiber Infection Model
6%
Optimal Dose
6%
Genome Analysis
6%
Resistance mutant
6%
Induced Resistance
6%
Therapeutic Potential
6%
Transcriptional Analysis
6%
Clarithromycin
6%
Clinical Centers
6%
Ceftaroline
6%
Current Treatment
6%
Enzymatic Mechanism
6%
Target-responsive
6%
THP-1 Cells
6%
Transpeptidase
6%
Kinetic Assay
6%
Infection Control Measures
6%
Resistance Mechanisms
6%
Success Strategies
6%
Peptidoglycan Synthesis
6%
Combination Regimen
6%
Drug Development
6%
Avibactam
6%
RNA-seq Analysis
6%
Acquired Antibiotic Resistance
6%
Hydrolysis Assay
6%
Mutant Strains
6%
Community-acquired Infections
6%
Underlining
6%
Drug Class
6%
Diagnostic Control
6%
Treatment Recommendations
6%
β-lactam Antibiotics
6%
Transplant Patients
6%
Compounds Interaction
6%
Amikacin
6%
Success Rate
6%
Cephalosporins
6%
Cefoxitin
6%
Immunosuppressed Population
6%
Pharmacology, Toxicology and Pharmaceutical Science
Lactam
100%
Beta Lactam
100%
Mycobacterium abscessus
57%
Infection
48%
Peptidoglycan
28%
Penicillinase
22%
Ceftazidime
12%
Imipenem
12%
Cystic Fibrosis
12%
Pharmacodynamics
6%
Gamma Glutamyltransferase
6%
Mouse Model
6%
Cephalosporin
6%
Ceftaroline
6%
Amikacin
6%
Drug Development
6%
Hospital Infection
6%
Cefoxitin
6%
Clarithromycin
6%
Community Acquired Infection
6%
Avibactam
6%
Carbapenem
6%
Beta Lactam Antibiotic
6%
Pharmacokinetics
6%
Antimicrobial Resistance
6%